Respiri investor Presentation, page-76

Did my analysis and came to the conclusion that investing in Respiri is way too risky for my risk preference. Especially execution risk. The current timeline suggest that commercial deployment of Wheezo's to happen in December, so I will wait around then to reevaluate the investment thesis. A lot of things have to go right in June due to the contract negotiations. Also, I would need to hear feedback from the Chinese hospitals that are trialling the product. However, I have more confidence in this management than the previous team. Will watch this with interest.

GLTAH